Domperidone: overview and clinical applications

Domperidone is a commonly used gastrointestinal motility drug, mainly used to relieve symptoms such as indigestion, gastric bloating, nausea and vomiting. Its core function is to enhance gastric motility and improve gastric emptying function by blocking peripheral dopamine receptors. This article will cover pharmacological effects, indications, usage and dosage, precautions and manufacturers, focusing on its clinical application and safety.

Pharmacological effects and indications

Domperidone promotes gastrointestinal motility by selectively antagonizing dopamine D2 receptors, and is particularly effective in treating symptoms related to delayed gastric emptying. Clinically, it is mainly used to treat functional dyspepsia, gastroesophageal reflux disease (non-erosive), and nausea and vomiting caused by chemotherapy and drugs. It should be noted that its effects are limited to the periphery and cannot easily pass through the blood-brain barrier, so there are fewer side effects on the central nervous system.

Usage, dosage and precautions

The usual dosage for adults is 10 mg three times a day, 15-30 minutes before meals. In children, dosage needs to be adjusted based on body weight. Common adverse reactions include dry mouth, headache, etc., but the incidence is low. Contraindications include gastrointestinal bleeding, patients with mechanical obstruction and those allergic to ingredients. Monitor for cardiac-related risks (e.g., QT interval prolongation) with long-term use.

Manufacturer and product information

Domperidone is produced by many pharmaceutical companies, and common trade names includeMorphine,MotiliumWait. The following is the main manufacturers and product information:

Summary and suggestions for rational medication use

As a gastrointestinal motility drug, domperidone must strictly follow the indications and dosage specifications and avoid off-label use. Patients should take medication under the guidance of a doctor or pharmacist, especially those with heart disease or electrolyte disorders. There is currently no evidence to support its use in infants and young children or for long-term treatment, and short-term symptomatic relief is still the main recommendation.

Quote sources:

1. "Chinese Expert Consensus on Functional Dyspepsia" (2015)
2. Domperidone package insert approval information from the National Medical Products Administration (NMPA)
3. Official product information of Xi'an Janssen Pharmaceutical Co., Ltd.